



BioTech (バイオテック) の現状:

—価値ある創造と革新—

2016年6月15日(水) | 5:30 PM - 9:00 PM

イベントの概要

プライスウォーターハウスクーパースのレポートによると、ここ最近のバイオ医薬品業界へのベンチャーキャピタルからの投資は、年間平均で60-70億ドルと史上最大の投資額を記録しています。世界的な金融政策の緩和の恩恵を受け、IPO(新規株式公開)で資金調達が可能なる中 M&A が急速に進み、収益の増加が強固になることによりベンチャーエコシステム全体に活気をもたらし、ハイリスク企業や若いスタートアップ企業への投資を促進する環境が確立されています。immune-oncology (がん免疫療法) や従来では治すことの出来なかった病気への治療など、業界における革新のパラダイムシフトは間違いなく企業と投資家双方に新たな機会をもたらしています。

業界の発展と成功に不可欠な、安定したビジネスモデルによる価値ある開発、既存の病気治療の革新についてパネリストの経験と意見を伺います。そして効果的な協業・M&A、そしてこれからも変わり続けるアメリカ国内外の法制度がもたらす問題と新たな可能性についても話し合います。

パネリスト: **Akiko Futamura** - President and CEO, InfiniteBio
Ken Horne - CEO, Symic Bio
Kazunori Maruyama - Exec Investment Director, Astellas Venture
Danny Ooi (Moderator) - Technical Regulatory Lead, Genentech/Roche

日時: **2016年6月15日(水)**
受付・ネットワーキング: 5:30 PM - 6:00 PM
プログラム: 6:00 PM - 8:15 PM
ネットワーキング: 8:15 PM - 9:00 PM

会場: **Wilson Sonsini Goodrich & Rosati**
650 Page Mill Road, Palo Alto, CA 94304

チケット情報: \$15: Early Bird Discount 5/28(土)11pm PST までにお申し込みの先着 30 名様
\$20: Regular Registration 6/11(土) 11pm PST までにお申し込みの方
\$35: Late Registration 6/13(月)正午までにお申し込みの方
\$50: 当日券 (お席に限りがございますのであらかじめご了承ください)

*会場にてお寿司、お飲み物をご用意いたしております

*チケットは <http://www.keizai.org> の EVENTS ページからお申し込みいただけます。

Featured Panelists and Moderator



Dr. Akiko Futamura is President and CEO of InfiniteBio. Formerly, she was Executive Vice President, Science and Technology/Business Development at SC BioScience USA, a subsidiary of Sumitomo Corporation, and Vice President, Science and Technology at Summit Biotech, a venture capital arm of Sumitomo Corporation. She was responsible for identifying key technologies, conducting due diligence and was involved in business development at therapeutics and platform (tool) companies. She played a key role in concluding a number of important alliances and investments with companies such as Morphotek, Cytellekt, QuantumDot Corporation, Xenogen, Panomics and Multispan. At InfiniteBio, Dr. Futamura has assisted numerous Japanese companies commercialize novel in vitro and in vivo technologies in the U.S., including PhoenixBio, SCIVAX Corporation, and ReproCELL. Dr. Futamura received her BS in biotechnology from the University of Tokyo, and Ph.D. in biochemistry from the University of Illinois. She is currently serving as a visiting professor at Osaka University, Japan, and is working to transfer novel technologies from Japan to the U.S. Dr. Futamura is a co-founder of the Japanese Scientists Network in the U.S.



Mr. Ken Horne has over 12 years of experience in the life science industry as an executive, entrepreneur and investor. He joined Symbic Bio as CEO in April 2014. Previously, he was a founding member of TauTona Group, an early stage life science venture capital fund. At TauTona, Mr. Horne founded Aline Aesthetics, a novel biomaterial company, where he led the company as General Manager until its acquisition by Allergan (AGN) in 2014. He also served as Vice President of Business Development for TauTona portfolio companies, which included acquisitions by LifeCell and Novadaq (NVDQ). Mr. Horne has a BS and MS degree from Stanford University in mechanical engineering. He serves on the board of the Bay Area Discovery Museum (non-profit), and is also a Kauffman Fellow.



Dr. Kazunori Maruyama is the executive investment director and the head of Astellas Venture Management (AVM), a California-based corporate venture arm of Astellas Pharma Inc. that is a top tier pharmaceutical company in Japan. Dr. Maruyama was appointed to the current position in December 2015. AVM is the fund management company with over \$200M under management and with 50 investment portfolio in total. Prior to the current position, Dr. Maruyama served as Director, Business Development/ Innovation Management at Astellas Pharma Inc. from 2008 to 2015. He joined pharmaceutical industry as a research scientist at Yamanouchi Pharmaceutical in 1991, where he led a team of molecular endocrinology. Dr. Maruyama was one of the founding members of the corporate venture arm of Yamanouchi Pharmaceutical and deeply contributed to the expansion of its portfolio by 9 investments from 2003-2007, which ended up with four successful exits to date. He holds a PhD from The University of Tokyo.



Dr. Danny Ooi is a CMC regulatory professional at Genentech Inc. (a member of Roche Group) serving as a key stakeholder in numerous early-late stage drug development programs and contributing to the development of technical and global/US regulatory strategies. He currently co-authors a book chapter on ICH Quality guidance. He previously worked for TLC Biopharmaceutical in business development/R&D and Burrill & Company, a life-science focused venture capital firm based in San Francisco. Dr. Ooi received a BA from University of California, Berkeley and a Ph.D. from Harvard University.



1990年に設立された経済シリコンバレーは、サンフランシスコ・ベイエリアでビジネスネットワークイベントを主催するNPOです。日米でビジネスを行う起業家や企業の成功の鍵となる重要なテーマについて、専門家を招いてディスカッション・交流する場を定期的に提供することを主な目的として、ボランティアによって運営されています。